July 12, 2013 | Bloomberg is reporting that a Bristol-Myers Squibb and Pfizer product approved last year was slowed by misconduct in its Chinese clinical trials. Derek Lowe breaks down the story and what it means for Chinese clinical trials. In the Pipeline